Green Pharmaceuticals Recalls SnoreStop NasoSpray Lot
Green Pharmaceuticals Inc is voluntarily recalling lot 2373/21222 of SnoreStop NasoSpray.
Green Pharmaceuticals Inc is voluntarily recalling lot 2373/21222 of SnoreStop NasoSpray.
The US FDA is warning consumers and healthcare providers to not use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) because these tests are not authorized, cleared, or approved by the FDA.
The FDA ordered Philips to notify patients and DMEs of the company’s June 14, 2021 recall of certain ventilators, CPAP, and BiPAP machines.
The FDA says an incorrect and non-specified polyester polyurethane, raw foam product, not intended for use in Trilogy Evo ventilators, was used to manufacture certain ventilators.
Read MoreThe US FDA updated the medical device shortage list to include all blood specimen collection tubes to the testing supplies and equipment – specimen collection category.
Read MoreThe FDA has warned consumers to stop using the LuSys Laboratories COVID-19 Antigen Test (Nasal/Saliva) and the LuSys Laboratories COVID-19 IgG/IgM Antibody Test.
Read MoreCovidien, LP (part of Medtronic) is recalling its Puritan Bennett 980 Series Ventilator due to a capacitor manufacturing assembly error that may cause the ventilator to become inoperable or stop working as intended, according to an FDA alert.
Read MoreThe FDA will withdraw temporary authorization for companies manufacturing alcohol-based hand sanitizer as part of the COVID-19 public health crisis.
Read MorePhilips Healthcare provided a statement in response to RT’s recent article, “Philips V60, V60 Plus HFO-equipped Ventilators Recalled Over Risk of Reduced Oxygen.”
Read MoreAccording to an FDA alert, Philips Respironics is recalling the V60 and V60 Plus ventilators that provide High Flow Therapy (Software Version 3.00 and Software Version 3.10) due to the risk to the patients who rely on the ventilator to provide high flow oxygen therapy if the system pressure reaches the default maximum limit.
Read MoreThe FDA has reported increased risks of myocarditis and pericarditis following vaccination with the Moderna and Pfizer-BioNTech COVID-19 vaccine.
Read MoreRegeneron’s COVID-19 monoclonal antibody cocktail (casirivimab + imdevimab) is now authorized at half the dose for patients age 12 and older.
Read MoreThe US FDA has requested a total budget of $6.5 billion as part of the President’s FY22 budget — a nearly 8% increase over FY21.
Read MoreThe US FDA has revoked an EUA for the monoclonal antibody bamlanivimab when administered alone, for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
Read MoreA Data & Safety Monitoring Board expressed concern that AstraZeneca may have included outdated information in a Phase 3 trial for its COVID-19 vaccine.
Read More